O	0	7	Genuine	Genuine	JJ	B-NP
O	8	18	monovalent	monovalent	JJ	I-NP
O	19	26	ligands	ligand	NNS	I-NP
O	27	29	of	of	IN	B-PP
O	30	34	TrkA	TrkA	NN	B-NP
O	35	40	nerve	nerve	NN	I-NP
O	41	47	growth	growth	NN	I-NP
O	48	54	factor	factor	NN	I-NP
O	55	64	receptors	receptor	NNS	I-NP
O	65	71	reveal	reveal	VBP	B-VP
O	72	73	a	a	DT	B-NP
O	74	79	novel	novel	JJ	I-NP
O	80	95	pharmacological	pharmacological	JJ	I-NP
O	96	105	mechanism	mechanism	NN	I-NP
O	106	108	of	of	IN	B-PP
O	109	115	action	action	NN	B-NP
O	115	116	.	.	.	O

O	117	127	Developing	Develop	VBG	B-VP
O	128	133	small	small	JJ	B-NP
O	134	142	molecule	molecule	NN	I-NP
O	143	152	agonistic	agonistic	JJ	I-NP
O	153	160	ligands	ligand	NNS	I-NP
O	161	164	for	for	IN	B-PP
O	165	173	tyrosine	tyrosine	NN	B-NP
O	174	180	kinase	kinase	NN	I-NP
O	181	190	receptors	receptor	NNS	I-NP
O	191	194	has	have	VBZ	B-VP
O	195	199	been	be	VBN	I-VP
O	200	209	difficult	difficult	JJ	B-ADJP
O	209	210	,	,	,	O
O	211	214	and	and	CC	O
O	215	217	it	it	PRP	B-NP
O	218	220	is	be	VBZ	B-VP
O	221	230	generally	generally	RB	I-VP
O	231	238	thought	think	VBN	I-VP
O	239	243	that	that	IN	B-SBAR
O	244	248	such	such	JJ	B-NP
O	249	256	ligands	ligand	NNS	I-NP
O	257	264	require	require	VBP	B-VP
O	265	274	bivalency	bivalency	NN	B-NP
O	274	275	.	.	.	O

O	276	284	Moreover	Moreover	RB	B-ADVP
O	284	285	,	,	,	O
O	286	298	multisubunit	multisubunit	JJ	B-NP
O	299	308	receptors	receptor	NNS	I-NP
O	309	312	are	be	VBP	B-VP
O	313	322	difficult	difficult	JJ	B-ADJP
O	323	325	to	to	TO	B-VP
O	326	332	target	target	VB	I-VP
O	332	333	,	,	,	O
O	334	341	because	because	IN	B-SBAR
O	342	346	each	each	DT	B-NP
O	347	354	subunit	subunit	NN	I-NP
O	355	366	contributes	contribute	VBZ	B-VP
O	367	369	to	to	TO	B-PP
O	370	376	ligand	ligand	NN	B-NP
O	377	385	affinity	affinity	NN	I-NP
O	385	386	,	,	,	O
O	387	390	and	and	CC	O
O	391	395	each	each	DT	B-NP
O	396	403	subunit	subunit	NN	I-NP
O	404	407	may	may	MD	B-VP
O	408	412	have	have	VB	I-VP
O	413	421	distinct	distinct	JJ	B-ADJP
O	422	425	and	and	CC	O
O	426	435	sometimes	sometimes	RB	B-VP
O	436	444	opposing	oppose	VBG	I-VP
O	445	454	functions	function	NNS	B-NP
O	454	455	.	.	.	O

O	456	460	Here	Here	RB	B-ADVP
O	460	461	,	,	,	O
O	462	465	the	the	DT	B-NP
O	466	471	nerve	nerve	NN	I-NP
O	472	478	growth	growth	NN	I-NP
O	479	485	factor	factor	NN	I-NP
O	486	494	receptor	receptor	NN	I-NP
O	495	503	subunits	subunit	NNS	I-NP
O	504	507	p75	p75	NN	I-NP
O	508	511	and	and	CC	O
O	512	515	the	the	DT	B-NP
O	516	524	tyrosine	tyrosine	NN	I-NP
O	525	531	kinase	kinase	NN	I-NP
O	532	536	TrkA	TrkA	NN	I-NP
O	537	541	were	be	VBD	B-VP
O	542	549	studied	study	VBN	I-VP
O	550	555	using	use	VBG	B-VP
O	556	566	artificial	artificial	JJ	B-NP
O	567	574	ligands	ligand	NNS	I-NP
O	575	579	that	that	WDT	B-NP
O	580	584	bind	bind	VBP	B-VP
O	585	597	specifically	specifically	RB	B-ADVP
O	598	600	to	to	TO	B-PP
O	601	606	their	their	PRP$	B-NP
B-Immaterial_anatomical_entity	607	620	extracellular	extracellular	JJ	I-NP
O	621	627	domain	domain	NN	I-NP
O	627	628	.	.	.	O

O	629	637	Bivalent	Bivalent	JJ	B-NP
O	638	642	TrkA	TrkA	NN	I-NP
O	643	650	ligands	ligand	NNS	I-NP
O	651	657	afford	afford	VBP	B-VP
O	658	664	robust	robust	JJ	B-NP
O	665	672	signals	signal	NNS	I-NP
O	672	673	.	.	.	O

O	674	681	However	However	RB	B-ADVP
O	681	682	,	,	,	O
O	683	690	genuine	genuine	JJ	B-NP
O	691	700	monomeric	monomeric	JJ	I-NP
O	701	704	and	and	CC	I-NP
O	705	715	monovalent	monovalent	JJ	I-NP
O	716	720	TrkA	TrkA	NN	I-NP
O	721	728	ligands	ligand	NNS	I-NP
O	729	735	afford	afford	VBP	B-VP
O	736	743	partial	partial	JJ	B-NP
O	744	751	agonism	agonism	NN	I-NP
O	751	752	,	,	,	O
O	753	761	activate	activate	VBP	B-VP
O	762	765	the	the	DT	B-NP
O	766	774	tyrosine	tyrosine	NN	I-NP
O	775	781	kinase	kinase	NN	I-NP
O	782	790	activity	activity	NN	I-NP
O	790	791	,	,	,	O
O	792	797	cause	cause	NN	B-NP
O	798	806	receptor	receptor	NN	I-NP
O	807	822	internalization	internalization	NN	I-NP
O	822	823	,	,	,	O
O	824	827	and	and	CC	O
O	828	834	induce	induce	VBP	B-VP
O	835	843	survival	survival	NN	B-NP
O	844	847	and	and	CC	O
O	848	863	differentiation	differentiation	NN	B-NP
O	864	866	in	in	IN	B-PP
B-Cell	867	871	cell	cell	NN	B-NP
I-Cell	872	877	lines	line	NNS	I-NP
O	878	881	and	and	CC	O
B-Cell	882	889	primary	primary	JJ	B-NP
I-Cell	890	897	neurons	neuron	NNS	I-NP
O	897	898	.	.	.	O

O	899	908	Monomeric	Monomeric	JJ	B-NP
O	909	912	and	and	CC	I-NP
O	913	923	monovalent	monovalent	JJ	I-NP
O	924	928	TrkA	TrkA	NN	I-NP
O	929	936	ligands	ligand	NNS	I-NP
O	937	940	can	can	MD	B-VP
O	941	950	synergize	synergize	VB	I-VP
O	951	955	with	with	IN	B-PP
O	956	963	ligands	ligand	NNS	B-NP
O	964	968	that	that	WDT	B-NP
O	969	973	bind	bind	VBP	B-VP
O	974	977	the	the	DT	B-NP
O	978	981	p75	p75	NN	I-NP
O	982	989	subunit	subunit	NN	I-NP
O	989	990	.	.	.	O

O	991	998	However	However	RB	B-ADVP
O	998	999	,	,	,	O
O	1000	1003	the	the	DT	B-NP
O	1004	1007	p75	p75	NN	I-NP
O	1008	1015	ligands	ligand	NNS	I-NP
O	1016	1020	used	use	VBN	B-VP
O	1021	1023	in	in	IN	B-PP
O	1024	1028	this	this	DT	B-NP
O	1029	1034	study	study	NN	I-NP
O	1035	1039	must	must	MD	B-VP
O	1040	1042	be	be	VB	I-VP
O	1043	1051	bivalent	bivalent	JJ	B-ADJP
O	1051	1052	,	,	,	O
O	1053	1056	and	and	CC	O
O	1057	1067	monovalent	monovalent	JJ	B-NP
O	1068	1071	p75	p75	NN	I-NP
O	1072	1079	ligands	ligand	NNS	I-NP
O	1080	1084	have	have	VBP	B-VP
O	1085	1087	no	no	DT	B-NP
O	1088	1094	effect	effect	NN	I-NP
O	1094	1095	.	.	.	O

O	1096	1101	These	These	DT	B-NP
O	1102	1110	findings	finding	NNS	I-NP
O	1111	1115	will	will	MD	B-VP
O	1116	1118	be	be	VB	I-VP
O	1119	1125	useful	useful	JJ	B-ADJP
O	1126	1128	in	in	IN	B-PP
O	1129	1138	designing	design	VBG	B-VP
O	1139	1142	and	and	CC	I-VP
O	1143	1153	developing	develop	VBG	I-VP
O	1154	1161	screens	screen	NNS	B-NP
O	1162	1164	of	of	IN	B-PP
O	1165	1170	small	small	JJ	B-NP
O	1171	1180	molecules	molecule	NNS	I-NP
O	1181	1190	selective	selective	JJ	B-ADJP
O	1191	1194	for	for	IN	B-PP
O	1195	1203	tyrosine	tyrosine	NN	B-NP
O	1204	1210	kinase	kinase	NN	I-NP
O	1211	1220	receptors	receptor	NNS	I-NP
O	1221	1224	and	and	CC	O
O	1225	1233	indicate	indicate	VBP	B-VP
O	1234	1238	that	that	IN	B-SBAR
O	1239	1249	strategies	strategy	NNS	B-NP
O	1250	1253	for	for	IN	B-PP
O	1254	1263	designing	design	VBG	B-VP
O	1264	1272	agonists	agonist	NNS	B-NP
O	1273	1275	of	of	IN	B-PP
O	1276	1288	multisubunit	multisubunit	JJ	B-NP
O	1289	1298	receptors	receptor	NNS	I-NP
O	1299	1306	require	require	VBP	B-VP
O	1307	1320	consideration	consideration	NN	B-NP
O	1321	1323	of	of	IN	B-PP
O	1324	1327	the	the	DT	B-NP
O	1328	1332	role	role	NN	I-NP
O	1333	1335	of	of	IN	B-PP
O	1336	1340	each	each	DT	B-NP
O	1341	1348	subunit	subunit	NN	I-NP
O	1348	1349	.	.	.	O

O	1350	1354	Last	Last	JJ	B-ADJP
O	1354	1355	,	,	,	O
O	1356	1359	the	the	DT	B-NP
O	1360	1368	strategy	strategy	NN	I-NP
O	1369	1371	of	of	IN	B-PP
O	1372	1377	using	use	VBG	B-VP
O	1378	1382	anti	anti	AFX	B-NP
O	1382	1383	-	-	HYPH	I-NP
O	1383	1391	receptor	receptor	NN	I-NP
O	1392	1396	mAbs	mAb	NNS	I-NP
O	1397	1400	and	and	CC	O
O	1401	1406	small	small	JJ	B-NP
O	1407	1415	molecule	molecule	NN	I-NP
O	1416	1423	hormone	hormone	NN	I-NP
O	1424	1430	mimics	mimic	NNS	I-NP
O	1431	1433	as	as	IN	B-PP
O	1434	1442	receptor	receptor	NN	B-NP
O	1443	1450	ligands	ligand	NNS	I-NP
O	1451	1456	could	could	MD	B-VP
O	1457	1459	be	be	VB	I-VP
O	1460	1467	applied	apply	VBN	I-VP
O	1468	1470	to	to	TO	B-PP
O	1471	1474	the	the	DT	B-NP
O	1475	1480	study	study	NN	I-NP
O	1481	1483	of	of	IN	B-PP
O	1484	1488	many	many	JJ	B-NP
O	1489	1494	other	other	JJ	I-NP
O	1495	1506	heteromeric	heteromeric	JJ	I-NP
B-Cellular_component	1507	1511	cell	cell	NN	I-NP
I-Cellular_component	1512	1519	surface	surface	NN	I-NP
O	1520	1529	receptors	receptor	NNS	I-NP
O	1529	1530	.	.	.	O

